Decision-making about complementary and alternative medicine by cancer patients: integrative literature review by Weeks, Laura et al.
                          Weeks, L., Balneaves, L., Paterson, C., & Verhoef, M. (2014). Decision-
making about complementary and alternative medicine by cancer patients:
integrative literature review. Open Medicine, 8(2), 54-66.
Publisher's PDF, also known as Version of record
License (if available):
CC BY-SA
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via Open Medicine at
http://www.openmedicine.ca/article/view/625/546. Please refer to any applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms.html
Open Medicine 2014;8(2)e54
Review                                                                                                                                                                                                                                                                    Weeks et al.
Decision-making about complementary and alternative 
medicine by cancer patients: integrative literature review 
Laura Weeks, Lynda G Balneaves, Charlotte Paterson, Marja Verhoef
ABSTRACT
Background: Patients with cancer consistently report conflict and anxiety when making decisions about comple-
mentary and alternative medicine (CAM) treatment. To design evidence-informed decision-support strategies, a 
better understanding is needed of how the decision-making process unfolds for these patients during their experi-
ence with cancer. We undertook this study to review the research literature regarding CAM-related decision- 
making by patients with cancer within the context of treatment, survivorship, and palliation. We also aimed to 
summarize emergent concepts within a preliminary conceptual framework.
Methods: We conducted an integrative literature review, searching 12 electronic databases for articles published 
in English that described studies of the process, context, or outcomes of CAM-related decision-making. We sum-
marized descriptive data using frequencies and used a descriptive constant comparative method to analyze state-
ments about original qualitative results, with the goal of identifying distinct concepts pertaining to CAM-related 
decision-making by patients with cancer and the relationships among these concepts. 
Results: Of 425 articles initially identified, 35 met our inclusion criteria. Seven unique concepts related to CAM and 
cancer decision-making emerged: decision-making phases, information-seeking and evaluation, decision-making 
roles, beliefs, contextual factors, decision-making outcomes, and the relationship between CAM and conventional 
medical decision-making. CAM decision-making begins with the diagnosis of cancer and encompasses 3 distinct 
phases (early, mid, and late), each marked by unique aims for CAM treatment and distinct patterns of information-
seeking and evaluation. Phase transitions correspond to changes in health status or other milestones within the 
cancer trajectory. An emergent conceptual framework illustrating relationships among the 7 central concepts is 
presented.
Interpretation: CAM-related decision-making by patients with cancer occurs as a nonlinear, complex, dynamic 
process. The conceptual framework presented here identifies influential factors within that process, as well as pa-
tients’ unique needs during different phases. The framework can guide the development and evaluation of theory-
based decision-support programs that are responsive to patients’ beliefs and preferences. 
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including an increasing amount of high-quality re-
search evidence, increased regulation and availabil-
ity of natural health products, improved regulation 
of qualified practitioners, and cultural trends that 
privilege more “natural” therapies and individual in-
volvement in self-care.6–8 
➢  It Is well establIshed that at least half of 
all patients with cancer use some form of comple-
mentary and alternative medicine (CAM) , such as 
acupuncture, massage, and natural health prod-
ucts, as part of their cancer care.1–5 Many factors 
contribute to the high prevalence of CAM use, 
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as systematic reviews, but their scope is broader. The 
intent is to synthesize a broad range of literature on 
an emerging topic with the goal of developing an in-
itial or preliminary model or framework.24 Through 
this review, we intended to propose a more compre-
hensive, holistic understanding of CAM and cancer 
decision-making than has been possible through any 
primary research study. 
Our search strategy was developed with the as-
sistance of a health librarian and included both 
subject headings and keywords related to cancer, 
decision-making, and CAM or integrative medi-
cine (online Appendix A). We searched the following 
electronic databases through September 2011: Aca-
demic OneFile, Alt HealthWatch, Allied and Comple-
mentary Medicine Database, CINAHL, EBSCO, Embase, 
MEDLINE, OmniFile, PsycINFO, PubMed, SocINDEX, 
and Sociological Abstracts. We included articles that 
described either or both of (1) the process or context 
of CAM decision-making relevant to cancer treatment, 
survivorship, or palliation; and (2) the outcomes of the 
decision-making process. We defined a “process” as a 
series of actions, changes, or reactions that happen over 
time as an individual contemplates CAM treatment 
options. We defined “context” as the set of circum-
stances within which decision-making takes place. We 
defined “outcomes” as the results of the decision-making 
process (and not of the cancer). Pertinent articles were 
included whether CAM decision-making was considered 
as a separate issue or as an issue alongside convention-
al medical decision-making. We excluded articles that 
described decision-making related to cancer preven-
tion and those that focused exclusively on CAM use 
or the context of CAM use, although (as stated above) 
we included articles that described the context of CAM 
decision-making. All of the authors participated in the 
screening process, with various pairs of authors in-
dependently screening each article title and abstract 
for eligibility. For articles where it was difficult to deter-
mine eligibility on the basis of title and abstract alone, 
the full text of the article was retrieved and examined 
before eligibility was determined. Screening decisions 
were recorded in an Excel database and were compared 
by one reviewer (L.W.) for consistency. Discrepancies 
were discussed and resolved during a team telecon-
ference during which all reviewers had access to all 
abstracts and/or full-text articles as required. Once a 
preliminary list of included articles had been developed, 
we reviewed the reference list of each article for other 
potentially eligible articles missed in the initial search.
Although CAM use has become common within can-
cer care, it remains controversial. Many CAM practices 
originate within philosophical traditions that deviate 
from Western medicine, leading some individuals to 
view them skeptically.9 Furthermore, the body of re-
search evidence for most CAM therapies tends to be 
smaller and often of lower quality than the evidence 
for conventional medical therapies.10,11 Existing CAM 
research evidence is also often difficult to find, synthe-
size, and share with appropriate knowledge users.12,13 
Finally, the potential for interactions with conventional 
cancer therapies is another common concern.14,15 
The controversies surrounding CAM use contrib-
ute to increased levels of conflict and anxiety for pa-
tients who contemplate using these therapies as part 
of their cancer care.12,16 For this reason, researchers 
have begun to explore how and in what context patients 
with cancer make decisions about CAM use, primarily 
in an effort to design supportive interventions. Many 
different perspectives have been explored, including 
those of people with a range of cancer types,16–18 those 
who have declined standard care,19,20 and those who 
identify with a specific ethnic group.21,22 It has become 
clear that CAM-related decision-making by patients 
with cancer (hereafter referred to as “CAM and cancer 
decision-making”) is a complex, dynamic, nonlinear, 
and highly individualized process. To design evidence- 
informed decision-support strategies, a better under-
standing is needed not only of how the decision- 
making process related to use of CAM unfolds during 
the cancer trajectory but also of the relevant concepts 
and relationships.
The purpose of this study was to review the research 
literature regarding CAM-related decision-making by 
patients with cancer within the context of treatment, 
survivorship, and palliation. Specifically, we were in-
terested in the process, context, and outcomes of CAM 
decision-making and how this decision-making pro-
cess relates to that associated with conventional med-
ical treatments. We aimed to summarize the literature, 
to synthesize its critical elements into a preliminary 
conceptual framework, and to make recommendations 
for future research.
Methods
We conducted an integrative literature review23 of Eng-
lish-language research articles published since 1998 
that describe CAM decision-making related to can-
cer treatment, survivorship, or palliation. Integrative 
literature reviews follow many of the same methods 
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and over half (19 [54%]) described studies that focused 
on all cancer types. One-third (12 [34%]) of the included 
articles described studies that explored CAM and cancer 
decision-making from the perspective of one or more 
special populations: various ethnic groups (6 [17%]), 
those who declined some form of conventional treat-
ment (5 [14%]), significant others (1 [3%]), and partici-
pants in phase I clinical trials (1 [3%]). The majority of 
these articles (25 [71%]) described qualitative research 
studies, whereas the others reported on cross-sectional 
surveys (5 [14%]), mixed-methods studies (3 [9%]), or 
synthesis research (2 [6%]). Table 1 summarizes the de-
scriptive results. 
Emerging concepts in the CAM and cancer decision- 
making literature
Seven unique concepts related to CAM and cancer 
decision-making emerged through our analysis: deci-
sion-making phases, information-seeking and evalua-
tion, decision-making roles, beliefs, contextual factors, 
decision-making outcomes, and the relationship be-
tween CAM and conventional medical decision-mak-
ing. Table 2 provides a guide to which articles included 
data relevant to each concept, and the results for each 
category are briefly synthesized below. 
Decision-making phases. The studies included in our 
review illustrate that CAM-related decision-making 
does not happen at any finite point in time but rath-
er occurs as a nonlinear, complex, dynamic process, 
of which therapy choices are one outcome.18,29,33 Al-
though each person follows his or her own unique CAM 
Descriptive data and results of the included studies 
were extracted from each article by one reviewer 
(L.W.). Descriptive data included such items as first 
author, article title, research purpose, sample size, 
and study design. In addition, the reviewer extracted 
verbatim result statements from each of the included 
studies. A quality assessment was not conducted, as 
such an assessment is outside the scope of an inte-
grative literature review. Descriptive data were ana-
lyzed by calculating frequencies for relevant categories 
within each variable. Result statements were analyzed 
through an iterative process, with the goal of identify-
ing distinct concepts relevant to CAM decision-making. 
The reviewer began by reading each article to ensure 
a comprehensive understanding of the content. Next, 
the reviewer extracted individual result statements 
and grouped them within Altas.ti qualitative software 
according to unique concepts within CAM decision- 
making that the statements represented. As each re-
sult statement was extracted, it was compared with 
all previously extracted statements, so that it could be 
grouped with similar statements or placed into a new 
category. Each category was labelled with a term to 
describe a concept within CAM decision-making that 
the statements in the category represented. Labels 
were emergent, based on careful reading of the data 
and regular team discussions, and were not necessarily 
borrowed from the reviewed articles, to avoid privil-
eging any particular perspective from the existing lit-
erature. In the course of this analysis, a set of 7 unique 
analytic categories emerged. The final step was to syn-
thesize the result statements within each category and 
propose a preliminary conceptual framework. One re-
viewer conducted the majority of the analysis; however, 
regular teleconferences and email discussions with the 
research team helped to confer authenticity within the 
emerging analytic categories.
The predefined review protocol is available from the 
corresponding author upon request.
Results
We identified 425 articles by searching the electronic 
databases and scanning reference lists. Of these, 35 
articles6,12,17–22,25–51 met our criteria and were included 
in the review (Figure 1). 
Descriptive analysis
Over half of the included articles (19 [54%]) described 
studies that had been conducted in Canada. The majority 
(31 [89%]) included participants with any stage of cancer, 
Potentially relevant articles 
identifi ed through database 
searches and scanning of 
reference lists n = 425
Studies included in literature 
review n = 35
Excluded  n = 362 
Not relevant on basis 
of title or abstract  
Full-text articles assessed 
for eligibility n = 63
Excluded  n = 28
Not relevant on basis 
of full-text review  
Figure 1 
Results of search strategy and process of identifying articles 
related to complementary and alternative medicine and 
decision-making by patients with cancer.
Open Medicine 2014;8(2)e57
Review                                                                                                                                                                                                                                                                    Weeks et al.
Ba
ln
ea
ve
s 
et
 a
l.1
2
To
 e
xp
lo
re
 th
e 
pe
rs
on
al
 a
nd
 s
oc
ia
l p
ro
ce
ss
es
 e
ng
ag
ed
 in
 b
y 
w
om
en
 
w
ith
 e
ar
ly
-s
ta
ge
 b
re
as
t c
an
ce
r w
he
n 
m
ak
in
g 
de
ci
si
on
s 
ab
ou
t C
A
M
 
du
rin
g 
th
e 
pe
rio
d 
fr
om
 d
ia
gn
os
is
 to
 s
ur
vi
vo
rs
hi
p
Em
er
ge
nt
, d
ev
el
op
ed
 
by
 a
ut
ho
rs
 (“
Br
id
gi
ng
 
th
e 
G
ap
”)
Br
ea
st
 (s
ta
ge
 I 
an
d 
II)
Ca
na
da
G
ro
un
de
d 
th
eo
ry
20
Ba
ln
ea
ve
s 
et
 a
l.2
5
To
 p
ro
vi
de
 a
 p
re
lim
in
ar
y 
de
sc
rip
tio
n 
of
 u
se
 o
f c
om
pl
em
en
ta
ry
 
th
er
ap
ie
s 
by
 w
om
en
 li
vi
ng
 w
ith
 b
re
as
t c
an
ce
r a
nd
 th
e 
pr
ed
is
po
si
ng
 
fa
ct
or
s 
as
so
ci
at
ed
 w
ith
 th
e 
de
ci
si
on
 to
 u
se
 c
om
pl
em
en
ta
ry
 th
er
ap
ie
s
N
ot
 s
ta
te
d
Br
ea
st
Ca
na
da
Cr
os
s-
se
ct
io
na
l s
ur
ve
y
64
Bi
sh
op
 a
nd
 
Ya
rd
le
y2
6 
To
 e
xp
lo
re
 th
e 
po
si
tio
ni
ng
 o
f p
eo
pl
e 
w
ith
in
 a
cc
ou
nt
s 
of
 
tr
ea
tm
en
t d
ec
is
io
ns
 a
nd
 th
er
eb
y 
to
 e
xp
lic
at
e 
st
ra
te
gi
es
 u
se
d 
to
 
m
an
ag
e 
id
eo
lo
gi
ca
l c
on
fl i
ct
 w
ith
in
 th
e 
co
nt
ex
t o
f o
rt
ho
do
x 
an
d 
co
m
pl
em
en
ta
ry
 m
ed
ic
in
e 
in
 c
an
ce
r
Po
si
tio
ni
ng
 th
eo
ry
A
ll
U
ni
te
d 
Ki
ng
do
m
D
is
co
ur
se
 a
na
ly
si
s
43
Bo
on
 e
t a
l.2
7  
To
 in
ve
st
ig
at
e 
th
e 
qu
es
tio
n,
 “A
re
 u
se
rs
 o
f C
A
M
 m
or
e 
au
to
no
m
ou
s 
th
an
 n
on
-u
se
rs
 w
ith
 re
sp
ec
t t
o 
pr
ob
le
m
-s
ol
vi
ng
 a
nd
 d
ec
is
io
n-
m
ak
in
g 
pr
ef
er
en
ce
s?
”
D
eb
er
–K
ra
es
tc
hm
er
 
pr
ob
le
m
-s
ol
vi
ng
 
de
ci
si
on
-m
ak
in
g 
sc
al
e
A
ll
Ca
na
da
Cr
os
s-
se
ct
io
na
l s
ur
ve
y
48
9
Bo
on
 e
t a
l.2
8
To
 e
xp
lo
re
 p
ro
st
at
e 
ca
nc
er
 p
at
ie
nt
s’ 
pe
rc
ep
tio
ns
, f
ee
lin
gs
, i
de
as
, a
nd
 
ex
pe
rie
nc
es
 re
ga
rd
in
g 
m
ak
in
g 
de
ci
si
on
s 
to
 u
se
 o
r n
ot
 u
se
 C
A
M
Pu
sh
–p
ul
l f
ac
to
rs
 
Pr
os
ta
te
Ca
na
da
Co
nt
en
t a
na
ly
si
s
29
Bo
on
 e
t a
l.2
9
To
 e
xa
m
in
e 
br
ea
st
 c
an
ce
r p
at
ie
nt
s’ 
pe
rc
ep
tio
ns
 o
f, 
ap
pr
oa
ch
es
 to
, a
nd
 
ex
pe
rie
nc
es
 w
ith
 C
A
M
Pu
sh
–p
ul
l f
ac
to
rs
 
Br
ea
st
Ca
na
da
Co
nt
en
t a
na
ly
si
s
36
Br
az
ie
r e
t a
l.3
0
To
 e
va
lu
at
e 
th
e 
im
pa
ct
 o
f p
ar
tic
ip
at
in
g 
in
 a
n 
in
te
gr
at
iv
e 
ca
nc
er
 c
ar
e 
pr
og
ra
m
 a
t t
he
 C
en
tr
e 
fo
r I
nt
eg
ra
te
d 
H
ea
lin
g 
in
 V
an
co
uv
er
, B
rit
is
h 
Co
lu
m
bi
a,
 o
n 
pa
tie
nt
s’ 
lif
es
ty
le
, q
ua
lit
y 
of
 li
fe
, a
nd
 o
ve
ra
ll 
w
el
l-b
ei
ng
N
ot
 s
ta
te
d
A
ll
Ca
na
da
In
te
rp
re
tiv
e 
de
sc
rip
tio
n
28
Br
oo
m
31
To
 u
nd
er
st
an
d 
ho
w
 in
di
vi
du
al
s 
w
ith
 c
an
ce
r m
ak
e 
de
ci
si
on
s 
ab
ou
t 
th
e 
le
gi
tim
ac
y 
of
 id
ea
s, 
ex
pe
rt
is
e,
 tr
ea
tm
en
ts
, a
nd
 re
gi
m
en
s 
in
 
th
e 
co
nt
ex
t o
f t
he
ir 
ca
nc
er
 a
nd
 to
 d
ev
el
op
 a
 c
on
ce
pt
ua
liz
at
io
n 
of
 
th
er
ap
eu
tic
 d
ec
is
io
n-
m
ak
in
g,
 u
si
ng
 th
e 
no
tio
n 
of
 b
ric
ol
ag
e*
 a
s 
a 
ke
y 
po
in
t o
f d
ep
ar
tu
re
N
ot
 s
ta
te
d
A
ll;
 in
te
ns
iv
e 
CA
M
 
us
er
s
Au
st
ra
lia
In
te
rp
re
tiv
e 
qu
al
ita
tiv
e 
re
se
ar
ch
20
Br
oo
m
 a
nd
 To
ve
y3
2
To
 e
xa
m
in
e 
in
di
vi
du
al
 c
an
ce
r p
at
ie
nt
s’ 
te
m
po
ra
l e
xp
er
ie
nc
es
 o
f C
A
M
, 
in
cl
ud
in
g 
(1
) t
he
 d
is
ci
pl
in
in
g 
of
 th
e 
se
lf 
de
m
an
de
d 
by
 c
er
ta
in
 C
A
M
 
th
er
ap
eu
tic
s 
an
d 
th
e 
im
pa
ct
 o
f t
ha
t o
n 
th
e 
ex
pe
rie
nc
e 
of
 h
av
in
g 
ca
nc
er
, (
2)
 th
e 
ro
le
 o
f C
A
M
 h
ea
lin
g 
th
er
ap
is
ts
 in
 re
co
nc
ep
tu
al
iz
in
g 
di
se
as
e 
an
d 
fi l
lin
g 
pe
rc
ei
ve
d 
ga
ps
 in
 b
io
m
ed
ic
al
 c
an
ce
r c
ar
e,
 a
nd
 
(3
) t
he
 c
om
pl
ex
 in
te
rp
la
y 
be
tw
ee
n 
CA
M
-d
er
iv
ed
 n
ot
io
ns
, s
el
f-h
ea
lin
g,
 
an
d 
th
e 
st
at
e 
of
 n
ea
rin
g 
de
at
h
N
ot
 s
ta
te
d
A
ll;
 in
te
ns
iv
e 
CA
M
 
us
er
s
U
ni
te
d 
Ki
ng
do
m
In
te
rp
re
tiv
e 
qu
al
ita
tiv
e 
re
se
ar
ch
8
Br
oo
m
 a
nd
 To
ve
y3
3
To
 e
xa
m
in
e 
ca
nc
er
 p
at
ie
nt
s’ 
pe
rs
pe
ct
iv
es
 o
n 
th
e 
na
tu
re
 o
f e
vi
de
nc
e 
an
d 
th
e 
de
gr
ee
 to
 w
hi
ch
 d
iff 
er
en
t u
nd
er
st
an
di
ng
s 
of
 e
vi
de
nc
e 
in
fo
rm
 
de
ci
si
on
-m
ak
in
g 
ab
ou
t C
A
M
 a
nd
 b
io
m
ed
ic
in
e
So
ci
al
 th
eo
ry
 
(p
os
tm
od
er
ni
ty
, 
re
fl e
xi
vi
ty
, 
te
ch
no
lo
gi
es
 o
f t
he
 
se
lf,
 d
ia
le
ct
ic
)
A
ll
Ca
na
da
In
te
rp
re
tiv
e 
qu
al
ita
tiv
e 
re
se
ar
ch
80
Br
ow
n 
et
 a
l.3
4
To
 e
lu
ci
da
te
 c
om
m
on
 th
em
es
 a
cr
os
s 
3 
st
ud
ie
s 
of
 w
om
en
’s 
de
ci
si
on
-
m
ak
in
g 
an
d 
to
 e
xa
m
in
e 
th
e 
pr
oc
es
s 
th
at
 w
om
en
 u
nd
er
go
 in
 m
ak
in
g 
an
 im
po
rt
an
t d
ec
is
io
n 
ab
ou
t t
he
ir 
he
al
th
 a
nd
 w
el
l-b
ei
ng
, i
nc
lu
di
ng
 
w
he
re
 a
nd
 h
ow
 th
ey
 a
cq
ui
re
 th
e 
ne
ce
ss
ar
y 
in
fo
rm
at
io
n 
to
 m
ak
e 
a 
de
ci
si
on
, t
he
 fa
ct
or
s 
th
at
 in
fl u
en
ce
 th
ei
r d
ec
is
io
n,
 w
ho
 s
up
po
rt
s 
th
em
 
in
 th
e 
de
ci
si
on
-m
ak
in
g 
pr
oc
es
s, 
an
d 
ho
w
 th
ey
 re
co
nc
ile
 c
on
fu
si
ng
 o
r 
co
nfl
 ic
tin
g 
in
fo
rm
at
io
n
Em
er
ge
nt
, d
ev
el
op
ed
 
by
 a
ut
ho
rs
Br
ea
st
Ca
na
da
Co
ns
ta
nt
 c
om
pa
ris
on
36
Ta
bl
e 
1
D
es
cr
ip
ti
ve
 in
fo
rm
at
io
n 
ab
ou
t 3
5 
ar
ti
cl
es
 d
es
cr
ib
in
g 
de
ci
si
on
-m
ak
in
g 
by
 p
at
ie
nt
s 
w
it
h 
ca
nc
er
Re
fe
re
nc
e
Pu
rp
os
e
U
se
 o
f t
he
or
y
Ca
nc
er
 ty
pe
, 
sp
ec
ia
l p
op
ul
at
io
n
Co
un
tr
y
M
et
ho
d 
or
 ty
pe
 
of
 a
na
ly
si
s
Sa
m
pl
e 
si
ze
Co
nt
in
ue
d 
on
 n
ex
t p
ag
e
Open Medicine 2014;8(2)e58
Review                                                                                                                                                                                                                                                                    Weeks et al.
Ta
bl
e 
1 
co
nt
in
ue
d
Re
fe
re
nc
e
Pu
rp
os
e
U
se
 o
f t
he
or
y
Ca
nc
er
 ty
pe
, 
sp
ec
ia
l p
op
ul
at
io
n
Co
un
tr
y
M
et
ho
d 
or
 ty
pe
 
of
 a
na
ly
si
s
Sa
m
pl
e 
si
ze
Ch
iu
 e
t a
l.3
5
To
 e
xp
lo
re
, i
n 
a 
sa
m
pl
e 
of
 C
hi
ne
se
 p
at
ie
nt
s 
w
ith
 c
an
ce
r, 
(1
) t
he
 
ge
ne
ra
l c
on
ce
pt
ua
liz
at
io
n 
of
 C
A
M
 u
se
, (
2)
 th
e 
m
ea
ni
ng
 o
f C
A
M
 u
se
 in
 
re
la
tio
n 
to
 c
an
ce
r, 
(3
) t
he
 p
at
te
rn
s 
of
 C
A
M
 u
se
 b
ef
or
e 
an
d 
af
te
r c
an
ce
r 
di
ag
no
si
s, 
(4
) t
he
 re
as
on
s 
fo
r C
A
M
 u
se
, a
nd
 (5
) t
he
 s
oc
io
cu
ltu
ra
l 
pr
oc
es
s 
in
 m
ak
in
g 
de
ci
si
on
s 
ab
ou
t C
A
M
 u
se
Em
er
ge
nt
, d
ev
el
op
ed
 
by
 a
ut
ho
rs
A
ll 
ty
pe
s 
(s
ta
ge
s 
I, 
II,
 a
nd
 II
I);
 C
hi
ne
se
 
pa
tie
nt
s
Ca
na
da
Co
ns
ta
nt
 c
om
pa
ris
on
14
Ev
an
s 
et
 a
l.3
6
To
 e
xp
lo
re
 th
e 
pr
oc
es
se
s 
sh
ap
in
g 
m
en
’s 
de
ci
si
on
-m
ak
in
g 
ab
ou
t C
A
M
 
an
d 
th
e 
ra
tio
na
le
s 
th
ey
 p
ro
vi
de
 fo
r t
he
ir 
vi
ew
s 
an
d 
be
ha
vi
ou
r
N
ot
 s
ta
te
d
M
al
e 
ca
nc
er
, a
ny
 
ty
pe
U
ni
te
d 
Ki
ng
do
m
Co
ns
ta
nt
 c
om
pa
ris
on
34
Ev
an
s 
et
 a
l.3
7
To
 e
xp
lo
re
 th
e 
us
e 
an
d 
ev
al
ua
tio
n 
of
 C
A
M
-r
el
at
ed
 in
fo
rm
at
io
n 
by
 
m
al
e 
ca
nc
er
 p
at
ie
nt
s
N
ot
 s
ta
te
d
M
al
e 
ca
nc
er
, a
ny
 
ty
pe
U
ni
te
d 
Ki
ng
do
m
N
ot
 s
pe
ci
fi c
; t
he
m
at
ic
34
G
ra
y 
et
 a
l.3
8
To
 e
xp
lo
re
 c
an
ce
r p
at
ie
nt
s’ 
m
ot
iv
at
io
ns
 fo
r s
ee
ki
ng
 in
fo
rm
at
io
n 
ab
ou
t 
un
co
nv
en
tio
na
l t
he
ra
pi
es
, t
he
ir 
de
ci
si
on
-m
ak
in
g 
pr
oc
es
se
s, 
th
ei
r 
ex
pe
rie
nc
es
 w
ith
 s
uc
h 
th
er
ap
ie
s, 
th
ei
r a
tt
em
pt
s 
to
 c
om
m
un
ic
at
e 
w
ith
 
co
nv
en
tio
na
l h
ea
lth
 c
ar
e 
pr
ac
tit
io
ne
rs
, a
nd
 th
ei
r p
er
ce
pt
io
ns
 o
f f
am
ily
 
m
em
be
rs
 a
nd
 fr
ie
nd
s’ 
re
ac
tio
ns
 to
 th
ei
r i
nt
er
es
t i
n 
un
co
nv
en
tio
na
l 
th
er
ap
ie
s
 N
ot
 s
ta
te
d
A
ll
Ca
na
da
N
ot
 s
pe
ci
fi c
; t
he
m
at
ic
32
H
lu
bo
ck
y 
et
 a
l.3
9
To
 d
es
cr
ib
e 
th
e 
ge
ne
ra
l u
sa
ge
 ra
te
s 
of
 b
io
lo
gi
ca
lly
 b
as
ed
 C
A
M
 a
m
on
g 
pa
rt
ic
ip
an
ts
 in
 p
ha
se
 I 
tr
ia
ls
; s
ec
on
da
ry
 o
bj
ec
tiv
es
 w
er
e 
to
 e
xp
lo
re
 
so
ci
al
 a
nd
 d
em
og
ra
ph
ic
 fa
ct
or
s 
as
so
ci
at
ed
 w
ith
 C
A
M
 u
se
, t
o 
de
sc
rib
e 
po
te
nt
ia
l d
iff 
er
en
ce
s 
in
 tr
ea
tm
en
t d
ec
is
io
n-
m
ak
in
g 
pr
ef
er
en
ce
s 
am
on
g 
CA
M
 u
se
rs
 a
nd
 n
on
-u
se
rs
, a
nd
 to
 in
ve
st
ig
at
e 
as
so
ci
at
io
ns
 o
f 
CA
M
 u
se
 w
ith
 a
w
ar
en
es
s 
of
 p
ro
gn
os
is
 a
nd
 q
ua
lit
y 
of
 li
fe
N
ot
 s
ta
te
d
Ad
va
nc
ed
 c
an
ce
r; 
ph
as
e 
I t
ria
l 
pa
rt
ic
ip
an
ts
U
ni
te
d 
St
at
es
Cr
os
s-
se
ct
io
na
l s
ur
ve
y
21
2
Jo
ne
s 
et
 a
l.2
2
To
 e
xp
lo
re
 th
e 
be
lie
fs
 a
nd
 a
tt
itu
de
s 
of
 A
fr
ic
an
 A
m
er
ic
an
 s
ur
vi
vo
rs
 o
f 
pr
os
ta
te
 c
an
ce
r r
eg
ar
di
ng
 th
e 
us
e 
of
 C
A
M
N
ot
 s
ta
te
d
Pr
os
ta
te
; A
fr
ic
an
 
A
m
er
ic
an
 p
at
ie
nt
s
U
ni
te
d 
St
at
es
Cr
os
s-
se
ct
io
na
l s
ur
ve
y 
an
d 
ph
en
om
en
ol
og
y
14
Ka
ka
i e
t a
l.4
0
To
 in
ve
st
ig
at
e 
et
hn
ic
 d
iff 
er
en
ce
s 
in
 h
ea
lth
 in
fo
rm
at
io
n–
se
ek
in
g 
be
ha
vi
ou
rs
 a
m
on
g 
ca
nc
er
 p
at
ie
nt
s 
of
 d
iv
er
se
 e
th
ni
ci
ty
 in
 H
aw
ai
i; 
al
so
, 
to
 e
xp
lo
re
 a
 p
os
si
bl
e 
as
so
ci
at
io
n 
be
tw
ee
n 
pa
tie
nt
s’ 
ed
uc
at
io
n 
an
d 
et
hn
ic
ity
 a
nd
 c
ho
ic
e 
of
 h
ea
lth
 in
fo
rm
at
io
n
N
ot
 s
ta
te
d
A
ll;
 v
ar
io
us
 e
th
ni
c 
gr
ou
ps
U
ni
te
d 
St
at
es
Co
rr
es
po
nd
en
ce
 
an
al
ys
is
14
0
Ki
m
by
 e
t a
l.4
1
To
 e
xa
m
in
e 
th
e 
re
la
tio
ns
hi
ps
 b
et
w
ee
n 
us
er
 p
ro
fi l
es
 
(s
oc
io
de
m
og
ra
ph
ic
 fa
ct
or
s, 
tr
ea
tm
en
t o
rie
nt
at
io
ns
, c
an
ce
r s
ta
tu
s)
 
an
d 
us
er
s’ 
ch
oi
ce
 o
f v
ar
io
us
 u
nc
on
ve
nt
io
na
l t
yp
es
 o
f t
re
at
m
en
t 
(in
di
vi
du
al
iz
ed
 v
er
su
s 
st
an
da
rd
iz
ed
 u
nc
on
ve
nt
io
na
l t
re
at
m
en
ts
)
N
ot
 s
ta
te
d
A
ll
D
en
m
ar
k
Cr
os
s-
se
ct
io
na
l s
ur
ve
y
44
1
M
ar
ko
vi
c 
et
 a
l.1
7
To
 e
xp
lo
re
 th
e 
im
pa
ct
 o
f s
pe
ci
fi c
 s
oc
ia
l a
nd
 c
ul
tu
ra
l f
ac
to
rs
 
in
fl u
en
ci
ng
 h
ea
lth
 c
ar
e 
de
ci
si
on
-m
ak
in
g
N
ot
 s
ta
te
d
G
yn
ec
ol
og
ic
Au
st
ra
lia
G
ro
un
de
d 
th
eo
ry
53
M
on
tb
ria
nd
42
To
 re
cr
ea
te
 a
 m
od
el
 re
fl e
ct
in
g 
th
e 
he
al
th
 d
ec
is
io
n 
re
al
iti
es
 o
f p
at
ie
nt
s 
w
ith
 a
 d
ia
gn
os
is
 o
f c
an
ce
r o
f t
he
 re
sp
ira
to
ry
 o
r d
ig
es
tiv
e 
sy
st
em
N
at
ur
al
is
tic
 a
nd
 
ra
tio
na
lis
tic
 re
se
ar
ch
; 
ph
en
om
en
ol
og
y;
 
he
ur
is
tic
s;
 T
ve
rs
ky
’s 
el
im
in
at
io
n-
by
-a
sp
ec
ts
 
th
eo
ry
; a
nd
 e
m
er
ge
nt
, 
de
ve
lo
pe
d 
by
 a
ut
ho
rs
 
Re
sp
ira
to
ry
 a
nd
 
di
ge
st
iv
e
Ca
na
da
Et
hn
og
ra
ph
y 
(fo
llo
w
in
g 
ph
en
om
en
ol
og
y)
 
30
0 
O
h 
an
d 
Pa
rk
43
To
 e
xp
lo
re
 h
ow
 p
at
ie
nt
s 
w
ith
 c
an
ce
r c
ho
os
e 
a 
th
er
ap
y 
af
te
r t
he
 
di
ag
no
si
s 
ha
s 
be
en
 m
ad
e 
an
d 
th
e 
de
ci
si
on
-m
ak
in
g 
st
ra
te
gi
es
 u
se
d 
by
 
th
es
e 
pa
tie
nt
s 
w
he
n 
th
ey
 v
is
it 
a 
do
ct
or
 o
r w
he
n 
th
ey
 u
se
 a
lte
rn
at
iv
e 
th
er
ap
ie
s
N
ot
 s
ta
te
d
A
ll
Ko
re
a
Co
gn
iti
ve
 
et
hn
og
ra
ph
ic
 d
ec
is
io
n 
tr
ee
 m
od
el
19
4 
Co
nt
in
ue
d 
on
 n
ex
t p
ag
e
Open Medicine 2014;8(2)e59
Review                                                                                                                                                                                                                                                                    Weeks et al.
Ta
bl
e 
1 
co
nt
in
ue
d
Re
fe
re
nc
e
Pu
rp
os
e
U
se
 o
f t
he
or
y
Ca
nc
er
 ty
pe
, 
sp
ec
ia
l p
op
ul
at
io
n
Co
un
tr
y
M
et
ho
d 
or
 ty
pe
 
of
 a
na
ly
si
s
Sa
m
pl
e 
si
ze
O
hl
én
 e
t a
l.4
4
To
 e
xp
lo
re
 h
ow
 s
ig
ni
fi c
an
t o
th
er
s 
w
er
e 
in
vo
lv
ed
 in
 c
an
ce
r p
at
ie
nt
s’ 
de
ci
si
on
-m
ak
in
g 
pr
oc
es
se
s 
re
la
te
d 
to
 C
A
M
N
ot
 s
ta
te
d
Br
ea
st
 a
nd
 
pr
os
ta
te
 (e
ar
ly
 
an
d 
ad
va
nc
ed
); 
si
gn
ifi 
ca
nt
 o
th
er
s
Ca
na
da
G
ro
un
de
d 
th
eo
ry
40
 w
ith
 e
ar
ly
 
ca
nc
er
; 2
1 
w
ith
 a
dv
an
ce
d 
ca
nc
er
; 3
1 
si
gn
ifi 
ca
nt
 
ot
he
rs
O
w
en
s2
1
To
 d
es
cr
ib
e 
th
e 
se
lf-
he
lp
 th
eo
re
tic
al
 fr
am
ew
or
k 
in
 re
la
tio
n 
to
 C
A
M
 
an
d 
to
 d
el
in
ea
te
 re
la
tio
ns
hi
ps
 in
 B
ra
de
n’
s 
Se
lf-
H
el
p 
M
od
el
 o
f s
id
e-
eff
 e
ct
 b
ur
de
n 
to
 u
nc
er
ta
in
ty
, C
A
M
 s
el
f-
ca
re
, a
nd
 q
ua
lit
y 
of
 li
fe
 in
 
H
is
pa
ni
c 
w
om
en
 u
nd
er
go
in
g 
tr
ea
tm
en
t f
or
 b
re
as
t c
an
ce
r 
Br
ad
en
’s 
Se
lf-
H
el
p 
Th
eo
ry
Br
ea
st
; H
is
pa
ni
c 
pa
tie
nt
s
U
ni
te
d 
St
at
es
Cr
os
s-
se
ct
io
na
l s
ur
ve
y
14
4
Ri
tv
o 
et
 a
l.4
5
To
 a
pp
ly
 a
 th
eo
re
tic
al
 m
od
el
, t
he
 R
is
k 
Ad
ap
ta
tio
n 
M
od
el
, t
o 
fu
rt
he
r 
th
e 
cl
in
ic
al
 u
nd
er
st
an
di
ng
 o
f t
he
 m
ot
iv
at
io
ns
 o
f c
an
ce
r p
at
ie
nt
s 
in
 
se
ek
in
g 
co
m
pl
em
en
ta
ry
 th
er
ap
ie
s
Ri
sk
 A
da
pt
at
io
n 
M
od
el
A
ll
N
ot
 o
rig
in
al
 
re
se
ar
ch
N
ot
 o
rig
in
al
 re
se
ar
ch
 
N
ot
 o
rig
in
al
 
re
se
ar
ch
Sh
um
ay
 e
t a
l.2
0
To
 e
xa
m
in
e 
ca
nc
er
 p
at
ie
nt
s’ 
re
as
on
s 
fo
r d
ec
lin
in
g 
al
l o
r p
ar
t o
f 
re
co
m
m
en
de
d 
ca
nc
er
 tr
ea
tm
en
t a
nd
 c
ho
os
in
g 
CA
M
M
on
tb
ria
nd
’s 
de
ci
si
on
-
tr
ee
 m
od
el
A
ll;
 v
ar
io
us
 e
th
ni
c 
gr
ou
ps
; p
at
ie
nt
s 
w
ho
 d
ec
lin
ed
 
co
nv
en
tio
na
l 
tr
ea
tm
en
t
U
ni
te
d 
St
at
es
Th
em
at
ic
14
Si
ng
h 
et
 a
l.6
To
 c
om
pa
re
 th
e 
pe
rc
ep
tio
ns
, b
el
ie
fs
, i
de
as
, a
nd
 e
xp
er
ie
nc
es
 th
at
 
co
nt
rib
ut
e 
to
 th
e 
de
ci
si
on
 o
f p
at
ie
nt
s 
w
ith
 p
ro
st
at
e 
ca
nc
er
 to
 u
se
 o
r 
no
t t
o 
us
e 
CA
M
N
ot
 s
ta
te
d
Pr
os
ta
te
; v
ar
io
us
 
et
hn
ic
 g
ro
up
s
U
ni
te
d 
St
at
es
Th
em
at
ic
27
Tr
ua
nt
 a
nd
 
Bo
tt
or
ff 1
8
To
 e
xa
m
in
e 
th
e 
de
ci
si
on
-m
ak
in
g 
pr
oc
es
s 
fo
r c
om
pl
em
en
ta
ry
 
th
er
ap
ie
s 
fr
om
 th
e 
pe
rs
pe
ct
iv
e 
of
 w
om
en
 w
ith
 b
re
as
t c
an
ce
r i
n 
th
e 
co
nt
ex
t o
f t
he
 c
an
ce
r t
ra
je
ct
or
y
Em
er
ge
nt
, d
ev
el
op
ed
 
by
 a
ut
ho
rs
Br
ea
st
Ca
na
da
G
ro
un
de
d 
th
eo
ry
16
Ve
rh
oe
f e
t a
l.4
6
To
 d
es
cr
ib
e 
th
e 
ty
pe
 o
f i
nf
or
m
at
io
n 
ab
ou
t C
A
M
 th
at
 p
at
ie
nt
s 
w
ith
 
ca
nc
er
 u
se
 in
 th
ei
r d
ec
is
io
n-
m
ak
in
g,
 to
 u
nd
er
st
an
d 
w
hy
 c
er
ta
in
 ty
pe
s 
of
 in
fo
rm
at
io
n 
ab
ou
t C
A
M
 a
re
 a
cc
ep
te
d 
as
 e
vi
de
nc
e 
by
 p
at
ie
nt
s 
w
ith
 
ca
nc
er
, a
nd
 to
 e
xp
lo
re
 th
e 
ro
le
 o
f s
ci
en
tifi
 c
 e
vi
de
nc
e 
in
 tr
ea
tm
en
t 
de
ci
si
on
-m
ak
in
g
N
ot
 s
ta
te
d
A
ll
Ca
na
da
Co
nt
en
t a
na
ly
si
s
27
Ve
rh
oe
f e
t a
l.4
7
To
 s
um
m
ar
iz
e 
an
d 
re
vi
ew
 th
e 
re
as
on
s 
fo
r C
A
M
 u
se
, a
s 
w
el
l a
s 
th
e 
so
ci
od
em
og
ra
ph
ic
 a
nd
 d
is
ea
se
 c
ha
ra
ct
er
is
tic
s 
as
so
ci
at
ed
 w
ith
 C
A
M
 
us
e 
am
on
g 
pa
tie
nt
s 
w
ith
 c
an
ce
r
N
ot
 s
ta
te
d
A
ll 
(fo
cu
s 
on
 b
re
as
t 
an
d 
pr
os
ta
te
)
U
ni
te
d 
St
at
es
, 
Ca
na
da
, W
es
te
rn
 
Eu
ro
pe
, A
si
a,
 
M
id
dl
e 
Ea
st
,  
Au
st
ra
lia
, N
ew
 
Ze
al
an
d
Sy
st
em
at
ic
 re
vi
ew
52
 a
rt
ic
le
s
Ve
rh
oe
f a
nd
 W
hi
te
19
To
 e
xp
lo
re
 w
hy
 a
nd
 h
ow
 p
at
ie
nt
s 
w
ith
 c
an
ce
r d
ec
id
e 
to
 fo
rg
o 
co
nv
en
tio
na
l t
re
at
m
en
ts
 in
 fa
vo
ur
 o
f a
lte
rn
at
iv
e 
tr
ea
tm
en
ts
, a
s 
w
el
l a
s 
w
hi
ch
 fa
ct
or
s 
in
fl u
en
ce
 th
is
 d
ec
is
io
n
N
ot
 s
ta
te
d
A
ll;
 p
at
ie
nt
s 
w
ho
 d
ec
lin
ed
 
co
nv
en
tio
na
l 
tr
ea
tm
en
t
Ca
na
da
Co
nt
en
t a
na
ly
si
s
31
Ve
rh
oe
f e
t a
l.4
8
To
 e
xp
lo
re
 c
an
ce
r p
at
ie
nt
s’ 
ex
pe
rie
nc
es
 w
ith
 a
nd
 e
xp
ec
ta
tio
ns
 o
f t
he
 
ro
le
 o
f f
am
ily
 p
hy
si
ci
an
s 
in
 d
is
cu
ss
in
g 
co
m
pl
em
en
ta
ry
 th
er
ap
ie
s
N
ot
 s
ta
te
d
A
ll
Ca
na
da
Co
nt
en
t a
na
ly
si
s
14
Co
nt
in
ue
d 
on
 n
ex
t p
ag
e
Open Medicine 2014;8(2)e60
Review                                                                                                                                                                                                                                                                    Weeks et al.
Ta
bl
e 
1 
co
nt
in
ue
d
Re
fe
re
nc
e
Pu
rp
os
e
U
se
 o
f t
he
or
y
Ca
nc
er
 ty
pe
, 
sp
ec
ia
l p
op
ul
at
io
n
Co
un
tr
y
M
et
ho
d 
or
 ty
pe
 
of
 a
na
ly
si
s
Sa
m
pl
e 
si
ze
W
hi
te
 e
t a
l.4
9
To
 e
xp
lo
re
 w
hy
 m
en
 d
ec
lin
e 
co
nv
en
tio
na
l p
ro
st
at
e 
ca
nc
er
 tr
ea
tm
en
t 
an
d 
us
e 
CA
M
 in
st
ea
d,
 to
 u
nd
er
st
an
d 
th
e 
ro
le
 o
f h
ol
is
tic
 h
ea
lin
g 
in
 
th
ei
r c
ar
e,
 a
nd
 to
 d
oc
um
en
t t
he
ir 
re
co
m
m
en
da
tio
ns
 fo
r h
ea
lth
 c
ar
e 
pr
ov
id
er
s
N
ot
 s
ta
te
d
Pr
os
ta
te
; p
at
ie
nt
s 
w
ho
 d
ec
lin
ed
 
co
nv
en
tio
na
l 
tr
ea
tm
en
t
Ca
na
da
Co
nt
en
t a
na
ly
si
s
29
W
hi
te
 a
nd
 V
er
ho
ef
 50
To
 e
xp
lo
re
 th
e 
ro
le
 o
f s
pi
rit
ua
lit
y 
in
 c
an
ce
r m
an
ag
em
en
t a
nd
 d
ec
is
io
n-
m
ak
in
g 
fo
r m
en
 w
ith
 p
ro
st
at
e 
ca
nc
er
 w
ho
 d
ec
lin
ed
 c
on
ve
nt
io
na
l 
tr
ea
tm
en
t
N
ot
 s
ta
te
d
Pr
os
ta
te
; p
at
ie
nt
s 
w
ho
 d
ec
lin
ed
 
co
nv
en
tio
na
l 
tr
ea
tm
en
t
Ca
na
da
Th
em
at
ic
10
W
hi
te
 a
nd
 V
er
ho
ef
 51
To
 e
xp
lo
re
 in
 d
ep
th
 h
ow
 s
en
se
 o
f c
on
tr
ol
 w
as
 re
la
te
d 
to
 th
e 
de
ci
si
on
 
to
 fo
rg
o 
co
nv
en
tio
na
l t
re
at
m
en
t f
or
 p
ro
st
at
e 
ca
nc
er
 a
nd
 to
 u
se
 C
A
M
 
th
er
ap
ie
s 
fo
r c
an
ce
r
N
ot
 s
ta
te
d
Pr
os
ta
te
; p
at
ie
nt
s 
w
ho
 d
ec
lin
ed
 
co
nv
en
tio
na
l 
tr
ea
tm
en
t
Ca
na
da
Co
nt
en
t a
na
ly
si
s
8
CA
M
 =
 c
om
pl
em
en
ta
ry
 a
nd
 a
lte
rn
at
iv
e 
m
ed
ic
in
e.
* B
ric
ol
ag
e 
w
as
 d
es
cr
ib
ed
 in
 th
is
 p
ap
er
 a
s 
th
e 
ac
tiv
e 
pr
oc
es
s 
in
 w
hi
ch
 p
eo
pl
e 
en
ga
ge
 to
 c
on
st
ru
ct
 th
ei
r u
ni
qu
e 
un
de
rs
ta
nd
in
g 
of
 C
A
M
, b
y 
pi
ec
in
g 
to
ge
th
er
 id
ea
s 
th
at
 fi 
t w
ith
 th
ei
r n
ee
ds
 a
nd
 e
xp
er
ie
nc
es
 fr
om
 d
iv
er
se
 p
ra
ct
ic
es
 a
nd
 
m
od
el
s 
of
 c
ar
e.
decision-making process, we identified 3 specific 
phases (which we labelled early, mid, and late) that 
correspond to different events across the cancer tra-
jectory, involving different aims and patterns of infor-
mation-seeking and evaluation.42 
The early phase of CAM decision-making begins with 
the initial diagnosis or a recurrence of cancer.18,28,37 It 
is characterized by feelings of fear and a sense of loss of 
control.28 A wide range of CAM therapies are typically 
contemplated12 during this phase, and the process in-
volves seeking and evaluating information regarding 
the pros and cons of each therapy and reaching a de-
cision regarding whether or not to use CAM, and if so, 
which type.12,29,34,35 Some people seem to move through 
this phase quickly and to spend little time, if any, re-
searching CAM options.18 Those with past CAM ex-
perience seem to fall into this category, as they tend to 
be less overwhelmed with the amount of available and 
conflicting information.18,46 Others spend more time 
consulting a range of information sources to help evalu-
ate the potential of CAM use.29 
The mid phase is best viewed as a maintenance 
phase, with the aim being to develop a personalized 
regimen of CAM therapies that fits within the individ-
ual’s beliefs and needs. Patients seem to transition to 
this phase of decision-making when they encounter 
some sort of positive change in their personal context, 
for example, once they have adapted psychologically to 
their cancer diagnosis or completed their convention-
al cancer treatment. CAM therapies used during this 
phase are directed toward maintaining well-being, con-
trolling the spread of cancer cells, managing the side 
effects of treatment, boosting the immune system, and 
preventing or delaying recurrence.18,47 
The late phase of decision-making includes the same 
iterative information-gathering and evaluation appar-
ent during the early phase, but there is less urgency, a 
stronger awareness of CAM, and more comfort with a 
variety of information sources.12 People seem to tran-
sition to this late phase when their conventional treat-
ment ends and they move into survivorship or palliative 
care.12,37 During the late phase, patients consider CAM 
therapies that help to address a variety of aims, includ-
ing overcoming a sense of loss and abandonment after 
discharge, maintaining health, prolonging life, or com-
ing to terms with impending death.37 In palliative situ-
ations, the patient may re-evaluate CAM regimens that 
were previously perceived to require too much time, 
money, and effort.32
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Transitioning between phases seems to correspond 
to times of crisis or change within the cancer experi-
ence42 that modify perceived consequences or expecta-
tions of CAM therapies within cancer treatment.45 Such 
changes seem to motivate people to revisit their origin-
al CAM-related decisions and to renew the process of 
gathering and evaluating information to help adapt to 
a new circumstance.12,18,37,38 This transitioning does not 
appear to represent desperation on the part of patients 
but, instead, a reasoned approach to critically examin-
ing their situation and available options.33 
Information-seeking and evaluation. Information- 
seeking and evaluation are integral components 
of decision-making, with distinct patterns during 
each phase. For some people, these activities form 
a process that begins at diagnosis and continues 
throughout their cancer journey. Other people begin 
to seek and evaluate information when they tran-
sition between decision-making phases and need 
to revisit their CAM decisions. People tend to rely 
on a wide range of information sources, including 
books, the Internet, mass media, CAM and conven-
tional practitioners, friends and family, and other 
cancer patients.12,17,18,20,29,35,36,37,49,51 Preferred in-
formation sources differ depending on the decision- 
making phase, with the broadest range of information 
sources used in early-phase decision-making, when 
individuals are exploring their treatment options and 
learning what types of CAM are available. In subse-
quent phases, individuals tend to rely on personal ex-
perience and the results of medical tests to evaluate 
whether CAM is helping them to achieve their treat-
ment goals.20,35,49,50,51 
The process of evaluating information has largely 
been studied by examining the meaning of evidence 
when cancer patients make CAM-related decisions. 
It is clear from our review of this literature that what 
constitutes high-quality evidence for the safety and 
effectiveness of CAM varies greatly among individuals46 
and also diverges from the standard applied within 
evidence-based medicine.12,36,45,51 The type and source 
of information that individuals accept as evidence seem 
to depend mostly on underlying beliefs and values, 
perceived credibility of information, experience with 
CAM, and stage of disease.18,29,31,36–38,46 Anxiety, eth-
nicity, and social support may also play a role.12,18,40 
Within CAM decision-making, information evaluation 
will play a stronger or weaker role, depending on the 
level of attention that the individual affords to a given 
content area and his or her beliefs regarding the poten-
tial for use of CAM to modify his or her condition.45 For 
example, if someone feels strongly that using herbal 
medicine can help mitigate the side effects of cancer 
treatment, and side effects are a great concern for that 
person, information evaluation becomes an important 
part of the decision-making process; however, if side 
effects are not as important an issue for the patient, 
then information evaluation in this situation is less 
important. 
Decision-making roles. Individuals tend to take either 
an active or a passive role in decision-making, and the 
role they choose may differ at different points during 
the decision-making process.12,26,29,36,39,42,45 People 
who take an active role appear more self-motivated,42 
have more self-confidence,12 and are more likely to 
have used CAM before their cancer diagnosis36,46 than 
those who take a passive role. The more active group 
also embraces a wider range of CAM therapies than 
the more passive group.36 Taking an active or passive 
role is associated with cancer type and state of ill-
ness: those with rare forms of cancer, faster-growing 
tumours, or advanced disease are more likely to take 
an active role.36 Regardless of whether their role is ac-
tive or passive, patients with cancer appear to experi-
ence CAM decision-making as problematic. Taking an 
active role often requires going against the socially 
sanctioned expertise of medical doctors and assuming 
responsibility for one’s own decisions, whereas taking 
a passive role conflicts with the ideal of individual 
responsibility for health.26 
Beliefs. A range of beliefs influence CAM and cancer 
decision-making, including beliefs about the causes of 
cancer,17,19,49,50 treatment mechanisms,20,37,50 risks and 
benefits of CAM use,6,12,17,19,20,22,25,28,29,34,35,42,43,46,49–51 
risks and benefits of conventional care,6,17–20,28,35, 
38,42,43,46,49–51 available evidence,18,19,31 and disease 
status.12,18,42,43,45 Although it is possible to categorize 
beliefs in this way, it is more likely that an individ-
ual’s entire belief system influences the CAM decision- 
making process, such that decisions are generally con-
gruent with the complexity of the belief system. De-
pending on an individual’s particular context at any 
given time, he or she will prioritize some beliefs over 
others when making decisions. For example, during 
active treatment, patients may prioritize their beliefs 
about treatment mechanisms and risks and benefits of 
care over their beliefs about the causes of their cancer. 
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It is clear, however, that not every person with can-
cer is explicitly aware of his or her beliefs; further-
more, these beliefs are not static. Current beliefs are 
informed by a range of factors, including past ex-
periences of the individual28 or his or her significant 
others,22 ethnocultural values,35,40 faith in God,22,42 
and education.40 
Contextual factors. Several contextual factors influ-
ence the experience of making CAM decisions, includ-
ing demographic and disease-related factors, social 
factors, and cultural norms. Relevant demographic and 
disease-related factors include age,33,47 geography,29,47 
disease status and active treatment,12,28,33,38,46 experi-
ence with CAM use,19,28,35,38,49 and income and ability 
to pay.21,29,35,38,47 Social factors centre on an individ-
ual’s interactions with others, including friends and 
family, health care practitioners, and other patients. 
Finding validation and support from others appears 
to be of great value to patients and seems to offer them 
the confidence to move forward with decisions that 
feel right for them.12,17,19,30,34,35,44 In some cases, how-
ever, support and recommendations from members of 
a support network can result in feelings of pressure 
and uncertainty.35,44 Cultural norms have a strong 
influence on decision-making and appear to reflect a 
conflict between CAM and biomedicine,12,33 the limits 
of biomedicine,6,17,28,29,35–37 and perceived harmless-
ness of many CAM therapies.28,29 
Decision-making outcomes. The CAM decision-mak-
ing process contributes to a range of outcomes, in-
cluding the decision to use or not use CAM, but also 
several others. The process of making a decision has 
been documented to empower individuals through 
more active participation in their own care,49 which 
can increase a person’s sense of control and thus re-
duce anxiety and fear.12,18,19,30,37,42,44,50,51 CAM deci-
sion-making also introduces individuals to different 
philosophies of healing, healthy lifestyle behaviours, 
and personal development.46 However, making deci-
sions about CAM may also be associated with certain 
difficulties. For example, common outcomes of CAM 
decision-making include conflict and resistance from 
clinicians, both of which can contribute to feelings 
of frustration and anxiety about making the “right” 
decision.12,30,31 Furthermore, individuals may de-
scribe feeling uncomfortable with the added respons-
ibility and self-accountability that use of CAM can 
bring.26,32,34 
Relationship between CAM and conventional med-
ical decision-making. Making decisions about CAM 
cannot be separated from making decisions about 
conventional medicine.6,28,34 These may seem to be 
similar processes that occur concurrently46; how-
ever, depending on the situation, one or the other will 
take priority.18 Furthermore, the goals of both de-
cision-making processes appear to be the same, but 
an individual’s beliefs and values will lead to a choice 
of either CAM or conventional treatment (or both) to 
achieve his or her treatment goals.6 
Synthesis
An emergent conceptual framework illustrating the 
relationship among the 7 central concepts is pre-
sented in Figure 2. In this framework, CAM decision- 
making begins with the diagnosis of cancer. The pro-
cess encompasses 3 distinct phases, each marked 
by unique patterns of information-seeking and 
evaluation, specifically, early-, mid-, and late-phase 
decision-making. Transitions between phases corres-
pond to changes in health status, a crisis, or other mile-
stones within the cancer trajectory. All decision-making 
phases are influenced by a myriad of contextual factors, 
including demographic and disease-related factors, so-
cial factors, cultural norms, and personal beliefs about 
cancer, its causes, and its treatments. Outcomes of the 
decision-making process include one or possibly mul-
tiple CAM decisions over time, and also shifts in per-
ceived sense of control, empowerment, anxiety, and 
fear, as well as conflict over whether the “right” deci-
sion has been made. 
Interpretation
Through this integrative literature review, we have 
created a conceptual framework for CAM and cancer 
decision-making that can be used to guide the develop-
ment of decision-support programs as well as future 
research in this field. The inclusion of diverse studies 
representing diverse populations ensures that the 
framework is comprehensive and therefore broadly 
applicable to cancer patients who are contemplating 
treatment options. It illustrates 3 distinct phases with-
in CAM and cancer decision-making, each character-
ized by different patterns of information-seeking and 
evaluation. It is also clear that CAM decision-making 
should not be considered as a process separate from 
decision-making related to conventional medical care. 
Beliefs, values, and other social and cultural norms 
guide all treatment choices, and some patients will 
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require support to articulate and prioritize these fac-
tors when making treatment decisions.
The inclusion of diverse study designs within inte-
grative literature reviews means that such reviews are 
more susceptible to lack of rigour than are other types 
of reviews (such as systematic reviews).24 For example, 
although our search was extensive, it is possible that we 
missed some primary studies, especially any published 
in languages other than English. However, given that 
we searched multiple databases and scanned reference 
lists of included articles for additional eligible stud-
ies, it is likely that we identified most of the published 
literature in this field. Furthermore, the reliability of 
our sampling strategy was enhanced by using pre - 
specified inclusion and exclusion criteria and by hav-
ing 2 reviewers screen each potentially relevant article. 
Data extraction within integrative literature reviews 
can be especially problematic because of the wide 
range of variables, theories, and populations exam-
ined within diverse primary studies. To provide focus 
and delineate boundaries for the review, our team met 
frequently to formulate a clear research purpose and 
related data-extraction strategy, as well as to discuss 
the analysis as it was emerging.24 Finally, our data an-
alysis strategy was compatible with strategies used to 
combine diverse data within mixed-methods studies,52 
further supporting the rigour of our review. 
We expect that the results of this review, including 
the conceptual framework and descriptions of relevant 
concepts within CAM and cancer decision-making, will 
be instructive for health care professionals who are 
supporting patients moving through this complex pro-
cess. Decisions about CAM use are often characterized 
by conflict and anxiety,12,16 perhaps more so in the set-
ting of cancer than other diseases, given the cultural 
significance of a cancer diagnosis.53 Decision-support 
programs are needed to promote open dialogue about 
the use of CAM in cancer care, to direct patients to 
high-quality information resources, and to support 
the safe integration of CAM within standard care.54 
This study has helped to identify some key character-
istics required of such decision-support programs. Of 
note, these programs should encompass a variety of 
strategies to support patients within different decision- 
making phases. They must also acknowledge the vari-
ability and complexity of individuals’ personal contexts, 
including beliefs, values, and social roles, which will 
influence when and how people make treatment deci-
sions. Decision-support programs must also be flexible 
and adaptive, to account for both active and passive 
BELIEFS
SOCIAL FACTORS 
CULTURAL NORMS 
Initial
diagnosis
 
• Treatment decisions
 Sense of control
 Empowerment
 Anxiety and fear
• Conict
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Conventional medical decision-making 
CAM decision-making phases 
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 Smaller number and types of CAM considered
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CAM decision-making outcomes
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Figure 2 
Conceptual framework of the decision-making process for complementary and alternative medicine (CAM) by patients with 
cancer. Conventional medical-decision making is included in this framework because making decisions about CAM cannot be 
separated from making decisions about conventional medicine. Social factors, cultural norms, and demographic and disease-related 
factors constitute the “contextual factors” discussed in the text. Transitions from one phase to another within the decision-making 
trajectory may occur at times of crisis or milestones, such as the end of conventional treatment and transition to survivorship or 
palliative care.
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decision-making roles, diversity in preferred informa-
tion sources, and changing needs and goals throughout 
the cancer experience. Finally, given that CAM-related 
decisions are intertwined with decision-making related 
to conventional medical treatments, it seems reason-
able that CAM decision-support programs should be 
integrated with other programs offered within stan-
dard care.
To date, most of the research in the field of CAM and 
cancer decision-making has been conceptual and ex-
ploratory. This perspective has been crucial to gaining 
a better understanding of the complexity within CAM 
decision-making. The integrative review presented 
here provides a comprehensive understanding of the 
CAM and cancer decision-making process, includ-
ing the distinct decision-making phases, roles, and 
contextual influences. It is now time to move forward 
with the development and evaluation of theory-based 
decision-support programs to provide evidence- 
informed support for cancer patients in making deci-
sions about CAM and conventional medical treatment. 
The proposed conceptual framework is a guide to en-
sure that decision-support programs are responsive 
to patients’ beliefs and preferences and appropriate to 
their unique needs at different points throughout the 
cancer trajectory. 
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